Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRRKCAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 426,250 shares of its common stock to 64 newly hired employees, consisting of inducement stock options to purchase an a
Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment
SRRKCAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, announced today that positive study results from the pivotal Phase 3 SAPPHIRE trial (NCT05156320) were published in the peer-reviewed journal The Lancet Neurology. The data showed that children and adults with SMA had improve
Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress
SRRKCAMBRIDGE, Mass.--(BUSINESS WIRE)--August 6, 2025-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today reported financial results and updates for the second quarter ended June 30, 2025. “Our BLA is progressing under priority review towards our September 22 PDUFA date, and our team is working with urgency to prepare
Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
SRRKCAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and additional severe and debilitating neuromuscular diseases, today announced positive results from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss. The trial demonstrated that 30% of
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRRKCAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 309,700 shares of its common stock to 11 newly hired employees, consisting of inducement stock options to purchase an aggregate of
Scholar Rock Holding Q1 EPS $(0.67) Misses $(0.65) Estimate
SRRKA Look Ahead: Scholar Rock Holding's Earnings Forecast
SRRKScholar Rock Names Vikas Sinha as CFO, Keith Woods as COO Amid Big Biotech Expansion Plans
SRRKScholar Rock Names Chair David Hallal as New CEO Taking Over From Jay Backstrom
SRRKScholar Rock Holding Corporation Says FDA Grants Priority Review For Biologics License Application And EMA Accepts Marketing Authorisation Application For Apitegromab As A Treatment For Spinal Muscular Atrophy
SRRKScholar Rock Holding Appoints Erin Moore As Interim Principal Financial Officer & Interim Principal Accounting Officer, Effective March 21, 2025
SRRKScholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment
SRRKScholar Rock will present new Phase 3 SAPPHIRE trial data on apitegromab at the 2025 MDA conference, highlighting efficacy and safety in SMA treatment.
Reported Earlier, Scholar Rock's New Phase 3 Trial Data Show Clinically Meaningful Improvements In Motor Function For Patients With SMA
SRRKScholar Rock Holding Q4 EPS $(0.61) Misses $(0.60) Estimate
SRRKScholar Rock Announces Additional Data Presentation From Phase 3 SAPPHIRE Trial On Spinal Muscular Atrophy At 2025 Muscular Dystrophy Association Conference
SRRKScholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth
SRRKScholar Rock aims for a 2025 launch of apitegromab in SMA, expecting $2 billion in global revenue and significant growth from upcoming trials and favorable data.
Scholar Rock Announces New Preclinical Data For SRK-439 Showing Significant Lean Mass Increase And Enhanced Fat Mass Loss With Metformin
SRRKScholar Rock To Present New Clinical And Biomarker Data From The Phase 1 DRAGON Trial At The SITC 39th Annual Meeting
SRRKScholar Rock Initiates Phase 2 EMBRAZE Trial Of Apitegromab In Obesity And Announces New Preclinical Data Showing SRK-439 Is 'more potent than an anti-ActRII antibody in maintaining lean mass in diet-induced obesity (DIO) mice'
SRRK